Abstract:Introduction: Trimetazidine is a metabolic agent of proven efficacy in the management of chronic coronary syndromes. According to guidelines, trimetazidine should be considered as a second-line treatment to reduce angina frequency and improve exercise tolerance in subjects whose symptoms are not adequately controlled by beta-blockers, calcium channel blockers and/or long-acting nitrates. Aim: This meta-analysis aimed to evaluate the efficacy of different doses (3 × 20 mg, 2 × 35 mg, 1 × 80 mg) of trimetazidine formulations in stable angina pectoris. Primary outcomes consisted of clinical parameters: numbers of weekly angina attacks and nitroglycerin usage. Method: Articles were collected from PubMed, Cochrane Library and Cochrane Central Register of Controlled Trials databases for the period from 1967 to 30 September 2019. Statistical analysis was performed by standard meta-analysis methods. Results: A total of 31 randomized controlled and observational trials, consisting of 9856 participants (mean age: 59.6 years, men: 61.6%) were included. Trimetazidine treatment, compared to placebo, reduced the number of weekly angina attacks (mean difference: –1.84, 95% CI: –2.39 to –1.30; p<0.0001) and reduced weekly nitroglycerin consumption (–1.65, 95% CI: –2.17 to –1.14; p<0.0001) in randomized trials. Trimetazidine treatment reduced the number of weekly angina attacks (–3.73, 95% CI: –4.53 to –2.92; p<0.0001) and nitroglycerin consumption (–3.23, 95% CI: –4.23 to –2.24; p<0.0001) in observational studies. No difference in angina reduction and nitroglycerin intake was observed between the three treatment doses (p = 0.57 and p = 0.48, respectively). Further results: the two primary variables decreased from visit to visit, higher enrollment angina rates and lower doses of trimetazidine were observed in shorter studies. Patients in shorter trials were younger than subjects in the longer ones. In shorter studies, the initial needs for nitroglycerin consumption and the following reduction were greater than those with longer duration. Conclusions: Regardless of dosage, trimetazidine has a favorable clinical effect in stable angina. New finding is that younger patients with more severe conditions show the most clinical benefit from treatment with trimetazidine. Orv Hetil. 2020; 161(16): 611–622.

New insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review

The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway

Abstract 12117: The Cardioprotection of Trimetazidine Against Ischemic Injury is Mediated by AMPK and ERK Signaling Pathway

ANTI-ISCHEMIC EFFECTIVENESS OF TRIMETAZIDINE 80 MG ONCE DAILY IN PATIENTS WITH STABLE ANGINA AND A HISTORY OF MYOCARDIAL INFARCTION. RESULTS OF THE METHOD STUDY

Regulatory effects of trimetazidine in cardiac ischemia/reperfusion injury

Effects of Trimetazidine on Ventricular Remodeling in Coronary Artery Disease Patients with Left Ventricular Hypertrophy: the Rationale and Design of a Randomized Controlled Trial.

GW28-e0241 Effects of Trimetazidine on Cardiac Function of Acute Myocardial Infarction Patients in China: A Meta-analysis

Efficacy of Trimetazidine in Aged Patients with Acute Myocardial Infarction

Effect of trimetazidine for PCI were related myocardial ischemia-reperfusion injury and prognosis

Function and Mechanism of Trimetazidine in Myocardial Infarction-Induced Myocardial Energy Metabolism Disorder Through the SIRT1–AMPK Pathway

[Clinical Outcomes of Trimetazidine in Patients with Acute ST Segment Elevation Myocardial Infarction Without ST Segment Resolution after Primary Percutaneous Coronary Intervention].

Role of Trimetazidine in Ameliorating Endothelial Dysfunction: A Review

Trimetazidine improves angiogenesis and tissue perfusion in ischemic rat skeletal muscle

Clinical Anti-Ischemic Effects of Trimetazidine in the Treatment of Stable Angina

Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency

Trimetazidine Effect on the Cardiac Autonomic Nerve System after Percutaneous Coronary Intervention in Coronary Heart Disease: A Propensity-score Matched Study

The effect of Trimetazidine to Percutaneous Coronary Intervention on the reperfusion of acute myocardial infarction.

Deciphering the inhibitory effects of trimetazidine on pulmonary hypertension development via decreasing fatty acid oxidation and promoting glucose oxidation

Progress of Trimetazidine in Treatment of Cardiovascular Diseases

[Clinical effect of various trimetazidine formulations in chronic coronary syndrome]

Trimetazidine ameliorates hindlimb ischaemic damage in type 2 diabetic mice